GLP-1 medications linked to reduced food cravings and unreported side effects

GLP-1 medications, such as semaglutide and tirzepatide, are being recognized for their ability to reduce ‘food noise’—the constant, intrusive mental chatter regarding food and cravings. Unlike gastric signals of fullness, these drugs appear to act on the brain’s reward circuitry, softening the dopamine-driven pull toward highly palatable foods and reducing compulsive eating habits.

A study published in Nature Health, which utilized AI to analyze 400,000 Reddit posts, has identified potential side effects that may not be prominently featured on official labels. While nausea, vomiting, and constipation are well-documented, researchers found frequent reports of fatigue, menstrual irregularities, chills, and hot flashes. The study notes that while these links are established, it is unclear if the symptoms are caused directly by the medication or are secondary effects of rapid weight loss. Additionally, the rise of a ‘gray market’ for these drugs outside of clinical supervision may increase the risk of side effects due to improper dosing or aggressive titration schedules.